Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio, Moderna, and Sorrento Therapeutics Stocks Rose Today

By Joe Tenebruso - Jun 24, 2020 at 6:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As COVID-19 cases surge, investors bid up coronavirus vaccine and treatment stocks.

What happened

Coronavirus-related biotechnology stocks rose on Wednesday, even as the major market averages fell sharply.

By the close of trading, shares of Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), and Moderna (MRNA) were up 10.7%, 8.6%, and 3%, respectively.

So what 

Inovio's gains were fueled in part by its announcement on Tuesday that it received $71 million in funding from the Department of Defense. Inovio will use the funds to manufacture its Cellectra handheld devices, which can be used to deliver the experimental INO-4800 vaccine directly into people's skin. 

A person is pointing to an upwardly sloping line that is above a downwardly sloping line.

COVID-19 stocks rose on Wednesday even as the market fell. Image source: Getty Images.

Moderna and Sorrento also likely benefited from investors' interest in companies that can potentially profit from helping to end the COVID-19 crisis. Moderna is currently conducting a Phase 2 study of its experimental coronavirus vaccine and plans to begin a Phase 3 study in July. Sorrento, meanwhile, is studying antibodies that it says can neutralize the novel coronavirus.  

Now what 

It's understandable that investors would seek shelter in coronavirus-related biotech stocks on a down day for most of the rest of the stock market, particularly when the major indexes declined primarily due to fears regarding surging COVID-19 case counts.

However, there can be no assurances that Inovio, Sorrento, or Moderna will be successful in their pursuits. More than 100 vaccines and treatments are currently being developed around the world. Competitors include healthcare giants Johnson & Johnson, Pfizer, and AstraZeneca, all of which have significantly more resources to invest in their development efforts. So, while Inovio, Sorrento, and Moderna have delivered solid gains to their investors, they remain relatively high-risk stocks.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.